Horizon Therapeutics Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Horizon Therapeutics Plc
August 03, 2022 15:58 ET
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Horizon Therapeutics plc ("Horizon Therapeutics” or...
Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 25, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42nd Annual...
Clinical Trials Market worth 81.6 billion by 2030, says Global Market Insights Inc.
June 13, 2022 06:15 ET
|
Global Market Insights Inc.
Selbyville, Delaware , June 13, 2022 (GLOBE NEWSWIRE) -- The clinical trials market value is expected to reach USD 81.6 billion by 2030, according to a new research report by Global Market...
ZEUS Scientific Announces FDA Clearance for the ZEUS dIFine® IFA Imaging and Pattern Recognition System
May 03, 2022 08:00 ET
|
ZEUS Scientific
BRANCHBURG, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has cleared ZEUS Scientific's dIFine® digital immunofluorescence system* for use with ZEUS' ANA HEp-2...
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
April 25, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022,...
Throne Biotechnologies Wins '5 Best BioTech Companies To Watch' Award From The Silicon Review
March 28, 2022 09:00 ET
|
Throne Biotechnologies Inc
PARAMUS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies (Throne), one of the global-leading biotech companies aiming to find a cure for type 1 diabetes and other autoimmune...
Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
March 22, 2022 16:06 ET
|
Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives as...
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
March 22, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
March 08, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December...
Fifth Update of ACR COVID-19 Vaccine Guidance Supports Fourth Doses for High-Risk Rheumatic Disease Patients
February 02, 2022 10:49 ET
|
American College of Rheumatology
Atlanta, Feb. 02, 2022 (GLOBE NEWSWIRE) -- The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and...